Jami Rubin of Goldman Sachs asks about the outlook for hepatitis C. CEO Rick Gonzalez said $ABBV expects to gain share in the hep C market in the US. He added that the company anticipates that it would get back into the $3Bil range.
$ARNC said that on the revenue contribution for 2017 and 2018, it would be small in 2017 as it would be the latter part of the year. In 2018, the contribution is dependent on the volumes the company ships through the plant.
$ILMN expects gross margin to be slightly lower in 2Q17 compared to 1Q17. The operating expense growth also is expected to the drive EPS. The company said that it is seeing new customers emerging in China and it remains bullish on the Chinese market opportunities.
$TXN said the demand was relatively broad based during 1Q17 from a product and end market perspective. By geography, on a year-over-year basis, revenue was up in Asia, Europe and the US, and was flat in Japan, added the company.